Monthly Archives: October 2022

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) the worlds largest science and public advocacy organization, representing 1,000 members announced today that Rachel King, co-founder and former CEO of GlycoMimetics, Inc., has agreed to serve as interim President and CEO. Kings appointment follows Dr. Michelle McMurry-Heath stepping down as President and CEO to serve as an Advisor to the Executive Committee of the BIO Board of Directors. The organization is searching for a full-time successor.

A long-standing member of the BIO leadership, King brings deep expertise across the industry and previously served as Chair of the BIO Board. King has experience at small and large companies having served as co-founder and former CEO of GlycoMimetics, Inc. and as a senior vice president of Novartis Corporation. Prior to that role she spent more than a decade at Genetic Therapy Inc., including as the companys CEO. She also served at ALZA Corporation and at Bain & Company. She is an expert in the innovation ecosystem as a former Entrepreneur in Residence at New Enterprise Associates, one of the nations leading venture capital firms.

I am deeply committed to the mission and vision of BIO. I look forward to working with BIOs talented staff and its members, said Rachel King, Interim President & CEO. Together, we are going to continue to tackle important policy issues related to health, agriculture, and the environment. Our work advances science and technology and touches people of all backgrounds to improve human health and well-being. The strategy of BIO remains on track.

We are delighted that Rachel King has agreed to take on this interim CEO role as we search for a successor. She is a highly experienced biotech executive who has served in large pharmaceutical organizations as well as an entrepreneur who co-founded her own biotech company. We look forward to working together with Rachel and the staff at BIO to continue important efforts that support innovation for people and patients in all aspects of biotechnology from food and agriculture to healthcare, said Paul Hastings, Chair BIO Executive Committee & Board of Directors.

King will be working closely with the BIO staff to advance innovation that benefits people and patients across BIOs key initiative areas: food and agriculture, industrial and environment, health biotechnology and emerging biotechnology companies.

About the Biotechnology Innovation Association (BIO)BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. For more information about us, please visit http://www.BIO.org and engage with us on Twitter at @IAmBiotech, on LinkedIn, or on YouTube.

Read more:
BIO Announces Appointment of Interim CEO - Business Wire

Sagah (centre) prepares to officiate the conference while, from left, Foo, Roslan, Yoon and Ahmad look on. Photo by Chimon Upon

KUCHING (Oct 12): Key government agencies, industry players, local venture capital (VC) companies, and government-linked companies (GLCs) are urged to play an active role to engage and collaborate in supporting and ensuring the growth and development of the countrys biotechnology towards translating research outcomes into commercialisable products and services.

Minister of Education, Innovation And Talent Development (MEITD) Datuk Roland Sagah Wee Inn believes that the 12th Asian Conference on Lactic Acid Bacteria (ACLAB12) will lay the foundation for such discussions and open up opportunities.

The main objective of ACLAB12 is to disseminate cutting-edge developments of LAB in tandem with the conference theme of Evidence-based LAB: advances, opportunities and challenges, which comprises eight tracks of scientific sessions.

The ACLAB12 will continue to be the primary platform to showcase the fast development of LAB-based research and technologies that will facilitate networking and collaborations with various stakeholders, he said prior to launching the four-day conference at Borneo Convention Centre Kuching (BCCK) yesterday.

Sagah said in Sarawak, the Sarawak Research Development Council (SRDC) looks into the research and development of new technological innovations derived from the states mega biodiversity of indigenous flora and fauna.

In particular, the Sarawak Biodiversity Centre (SBC), an agency under MEITD Sarawak, is well-endowed with a diverse wealth of biological resources; that is biodiversity that potentially has unique applications in healthcare, agriculture and industries.

However, bioprospecting of biodiversity to discover potential and valuable applications very much depends on implementing a highly robust research and development (R&D) programme involving various scientific tools, including biotechnology. Therefore, the centre is entrusted to initiate intensive biotech-based research and development on the states biological resources, he said.

Sagah noted that among the challenges and constraints facing the country now are lack of capital or follow-up funding for commercialisation, and lack of talent in specific expertise.

However, all these problems can be addressed if all stakeholders mobilise their energy to support the countrys biotechnology ecosystem, including providing a conducive environment to increase the number of international-level local researchers.

Furthermore, the strengthening and empowerment of the countrys biotechnology ecosystem need to be implemented in line with the transformation of the policy strategy and governance that has been identified in the National Biotechnology Policy 2.0 (NBP 2.0), he said.

Sagah pointed out that the ACLAB12 theme is very much aligned with the recently launched NBP 2.0 to ensure that the biotechnology field will develop rapidly and advance in line with the aspiration of making Malaysia a high-tech or k-economy country by 2030.

He said the policy will strengthen the existing biotechnology ecosystem to be a catalyst in solving national challenges related to food security, pandemic management, and climate change crisis through locally developed biotechnological solutions.

I am very much encouraged that the industry players have come together to jointly develop high-impact initiatives to produce new food products and the processed supplement food industry.

These are high-yield food manufacturing sectors, and we need the collaboration and support of the private sector to maximise the potential of these niche probiotic and superfood products developed from lactic acid bacteria (LAB)-based research and technologies, he said.

More than 150 scientists, academicians, industries and resource persons from the government, private sector and non-governmental organisations (NGOs), both local and international, are participating in the international conference on Lactic Acid Bacteria (LAB).

The 12th edition of the annual international scientific conference was organised by Malaysian Society for Lactic Acid Bacteria (MSLAB) with co-organisers Universiti Putra Malaysia, Universiti Malaysia Sarawak (Unimas), Universiti Teknologi MARA, Universiti Malaysia Terengganu, Universiti Kebangsaaan Malaysia, University of Nottingham Malaysia, UCSI University, MAHSA University and Dong Foong Manufacturing Sdn Bhd.

MSLAB is under the auspices of the Asian Federation for Lactic Acid Bacteria (AFLSAB), which has members from all over Asia, such as China, Taiwan, India, Indonesia, Iran, Japan, Mongolia, The Philippines, Singapore, South Korea, Thailand and Vietnam. Every year, members take turns to host the conference in their home country, where the conference acts as a primary platform to showcase the fast development of Lactic Acid Bacteria (LAB)-based research, technology, network and collaboration with various stakeholders.

Also present were Malaysian Society for Lactic Acid Bacteria (MSLAB) president and ACLAB12 chairperson Prof Dr Foo Hooi Ling, Asian Federation of Societies for Lactic Acid Bacteria (AFSLAB) president Prof Dr Yoon Sung-Sik, Universiti Putra Malaysia (UPM) vice-chancellor Dato Prof Dr Mohd Roslan Sulaiman, and Universiti Malaysia Sarawak (Unimas) deputy vice chancellor (Academic and International) Prof Dr Ahmad Hata Rasit.

Facebook Messenger Twitter WhatsAppEmailPrint

Read more from the original source:
Stakeholders urged to play active role in R&D on biotechnology - The Borneo Post

Unity Biotechnology, Inc.

-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT/8:00 a.m. ET-

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host an Investor/Analyst Day on Wednesday, October 12, 2022 at 5:00 a.m. PT/8:00 a.m. ET to discuss the current treatment landscape and unmet medical need for age-related diseases of the eye, and the potential treatment solution that UNITYs lead program, UBX1325, may provide.

Members of UNITYs senior management team and Key Opinion Leader Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of Medicine) will discuss the proposed mechanism of action of UBX1325 and new preclinical data that supports the senolytic approach in retinal diseases, the most recent UBX1325 clinical data from the BEHOLD study in Diabetic Macular Edema (DME), the ENVISION study in wet Age-related Macular Degeneration (wet AMD), including details of the new 48-week long-term follow-up extension study and near-term value driving milestones.

The live webcast can be accessed in the Investors and Media section of our website, http://www.unitybiotechnology.com, under Events & Presentations or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the Investors & Media section of our website, under Events and Presentations.

About UNITYUNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITYs current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at http://www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Story continues

Source: Unity Biotechnology, Inc

More here:
UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye - Yahoo...

To get a sense of who is truly in control of Nautilus Biotechnology, Inc. (NASDAQ:NAUT), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 33% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

And looking at our data, we can see that insiders have bought shares recently. So the news of stock price falling by 18% is not something they might have been expecting soon after purchasing shares.

Let's take a closer look to see what the different types of shareholders can tell us about Nautilus Biotechnology.

Check out the opportunities and risks within the US Life Sciences industry.

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Nautilus Biotechnology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nautilus Biotechnology's historic earnings and revenue below, but keep in mind there's always more to the story.

Nautilus Biotechnology is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Nautilus Biotechnology's case, its Top Key Executive, Parag Mallick, is the largest shareholder, holding 17% of shares outstanding. In comparison, the second and third largest shareholders hold about 14% and 14% of the stock. Interestingly, the third-largest shareholder, Sujal Patel is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.

Our research also brought to light the fact that roughly 52% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Nautilus Biotechnology, Inc.. Insiders own US$78m worth of shares in the US$238m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

The general public, who are usually individual investors, hold a 12% stake in Nautilus Biotechnology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private equity firms hold a 27% stake in Nautilus Biotechnology. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

We can see that Private Companies own 3.3%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 3 warning signs we've spotted with Nautilus Biotechnology (including 2 which can't be ignored) .

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Find out whether Nautilus Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

More:
After buying recently, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders must be dismayed to see the company's market cap drop to US$238m - Simply...

The Industrial Biotechnology Innovation Centre (IBioIC) has appointed a new senior business engagement manager to accelerate the growth of Scotlands bioeconomy and achieve ambitious targets set out in the National Plan for Industrial Biotechnology.

Andrew Bowen joins IBioIC from Oxford University Innovation, where he was a senior licensing and ventures manager, focusing on commercialising a variety of high-impact chemistry and life sciences projects. Additionally, he led the formation of spin-outs from Oxford University, helping them develop their business plan, build teams and secure seed funding.

Andrew Bowen, senior business engagement manager at The Industrial Biotechnology Innovation Centre (IBioIC)

Since 2016, Andrew has also been a board observer at Oxford University spin-out company EnzBond Limited, which aims to change the current understanding of biocatalysts.

In his new role, Andrew will lead Biotech Innovators a new accelerator programme for SMEs, spinouts and start-ups launched earlier this month. He will also help to raise awareness of funding opportunities for companies in the IBioIC network and accelerate the commercialisation of strategic projects throughout the sector.

Andrew Bowen said: Im excited to join IBioIC and apply my experience across its range of projects. The innovation centres network includes so many fantastic companies using cutting-edge techniques and processes, and Im looking forward to connecting with them and exploring how IBioIC can support them further. Biotechnology presents a great opportunity to embrace the net zero targets for Scotland and Im keen to be part of the great work IBioIC does to reach these goals.

Mark Bustard, CEO of IBioIC, added: Andrew is an excellent addition to IBioIC. Having managed a large portfolio of projects within the chemistry and life sciences sectors in his role at Oxford, he brings a wealth of experience to the team. IBioICs main objective is to grow the bioeconomy in Scotland and Andrew will play a key role in connecting research teams with industry partners. We look forward to working with him as we continue to support companies in their journey towards net zero.

Read more of our People & Skills articles here

Follow this link:
IBioIC strengthens team with appointment from Oxford University Innovation - The Manufacturer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), http://www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Kumaraguru Raja has joined the firms healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap Biotechnology companies across the therapeutic space, with an initial focus on companies developing novel drugs for infectious diseases, inflammatory diseases, neurological disorders, oncology, and womens health.

Prior to joining ROTH, Dr. Raja was a senior biotechnology analyst at Brookline Capital Markets from 2017 to 2022, where he focused on small and microcap companies. He started his equity research career in 2010 as a Senior Associate Analyst on the Citi Research biotechnology team covering large-cap biotechnology companies. His expertise includes bottom-up scientific and financial analysis on companies across therapeutic areas and across a spectrum of market capitalizations. He focuses on drug development, intellectual property, FDA and EMA regulations, reimbursement coverage and clinical science. He conducted postdoctoral research at Mayo Clinic on the epigenetic causes of cancer and at Los Angeles Biomedical Research Institute on the molecular mechanisms concerning the role of human bone marrow stem cells in normal and leukemic hematopoiesis. He received a Ph.D. in Biological Sciences from Bowling Green State University and an MBA from University of California, San Diego.

Jeff Martin, CFA - Director of Research, commented, ROTH continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform. Im pleased to welcome Kumar to our thought-leading biotechnology research team. His strong academic background combined with his experience covering innovative and underappreciated biotechnology companies will undoubtedly serve our clients well.

Dr. Raja commented, I am enthusiastic to join ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research portfolio. My goal is to provide a significant contribution by analyzing companies to identify unique companies developing innovative treatments for diseases with significant unmet need with favorable risk-reward for investors.

We are excited to have Kumar on our healthcare research team, said Byron Roth, CEO of ROTH. His addition further demonstrates our unwavering commitment to the life sciences sector. Im confident that Kumars expertise in biotechnology will enhance our ability to continue to build upon our over 10-year track record of success in assisting both companies and investors in the healthcare sector.

Since 2010, ROTH has been involved in approximately 550 transactions for its Healthcare clients, with total transaction value over $24.8 billion. (Source: ROTH Capital Partners | 09/29/2022)

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.

Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit http://www.roth.com.

More:
ROTH Capital Partners Announces the Addition of Kumaraguru Raja, Ph.D. to its Healthcare Research Team - Business Wire

The 16th Edition of the Pan-Asia Farmers Exchange Program started on October 10, 2022, and will last until October 14, 2022, in the Philippines. The program is organized to provide a platform for knowledge sharing and exchange on agricultural plant biotechnology.

Several participants including farmer leaders, scientists, academia, media, government officers, and policymakers will be present at this week-long program.

The 14th and 15th editions of the Pan-Asia Farmers Exchange Program held in 2020 and 2021 respectively, were held virtually.

Founder and Editor-in-Chief, Krishi Jagran, M C Dominic addressed the 16th Edition of Pan-Asia Farmers Exchange Program today in the Philippines. While addressing who's who, he stressed upon bringing the technology that can increases farm income.

Today, the second day of this program witnessed many eminent speakers sharing experiences and knowledge on biotech.

Ma. Lorelie Agbagala, Head of the Secretariat of the National Committee on Biosafety of the Philippines talks about the Philippine Biosafety Regulations on Plants derived from Modern Biotechnology.

Dr. Lilia Portales, Supervising Agriculturist at the Philippine Department of Agriculture- Bureau of Plant Industry, shares the Insect Resistance Management for Biotech Corn.

Jerome Barradas, Project Coordinator of the Research and Thought Leadership Department at SEARCA, discusses about Communicating Biotechnology.

Jenny Panopio, Chair of the CropLife Philippines Seeds Team, shared Philippine experiences in communicating biotechnology.

David Cristobal, Chair of the CropLife Philippines (CLP) Stewardship and Responsible Care Committee, talks about CLP's stewardship programs focusing on the Sustainable Corn Production in Sloping Areas and Use of Authorized Seeds.

First published on: 11 Oct 2022, 11:17 IST

Dear patron, thank you for being our reader. Readers like you are an inspiration for us to move Agri Journalism forward. We need your support to keep delivering quality Agri Journalism and reach the farmers and people in every corner of rural India. Every contribution is valuable for our future.

Originally posted here:
Experts at 16th Edition of Pan-Asia Farmers Exchange Program Discusses About Agriculture Biotechnology - Krishi Jagran

The most recent report published by Market Research Inc. indicates that the Animal Health Biotechnology Market is likely to accelerate significantly in the next few years. Specialists have studied market drivers, restraints, risks and prospects in the global market. The Animal Health Biotechnology Market report shows the likely direction of the market in the coming years along with its assessments. A meticulous study purposes to understand the market price. By analyzing the competitive landscape, the authors of the report have made excellent efforts to help readers understand the key business strategies that significant organizations are utilizing to keep up with market sustainability.Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals.

Key Players in the Animal Health Biotechnology Market Research Report:Bayer AG, Merck & Co.Inc., Pfizer Inc., Sanofi, Santa Cruz Biotechnology

Get a Sample Copy of Report: https://www.marketresearchinc.com/request-sample.php?id=115348

The report includes organizational profiles of virtually all major players in the Animal Health Biotechnology market. The Company Profiles segment provides important analysis of strengths and weaknesses, business trends, recent advances, mergers and acquisitions, expansion plans, global presence, market presence, and portfolios of products from significant market players. This data can be used by players and other market members to expand their productivity and streamline their business strategies.

By Type:Feed AdditivesPharmaceuticalsVaccines

By Application:Production AnimalsCompanion Animals

:The research report extensively lists the regional landscape of this industry. According to the review, Animal Health Biotechnology Market regional landscape is bifurcated into , , , , and .The study provides significant data relating to the market share that every region is estimated to hold, in tandem with the growth opportunities anticipated for each geography.The report describes the growth rate in which each geography is estimated to register over the forecast time period.

Get Exclusive Discount: https://www.marketresearchinc.com/ask-for-discount.php?id=115348

The global market for Animal Health Biotechnology is segmented on the basis of product, type. These segments have been concentrated separately. The detailed examination permits evaluation of the factors influencing the Animal Health Biotechnology Market. Specialists have analyzed the nature of growth, investments in research and development, changing utilization patterns, and rising number of applications. Furthermore, experts have additionally assessed the changing economics around the Animal Health Biotechnology Market that are likely affect its course.

The report's regional analysis segment allows players to focus on high-growth regions and countries that could help them to expand their presence in the Animal Health Biotechnology market. Aside from expanding their footprint in the Animal Health Biotechnology market, the regional analysis assists players to increase their sales while having a better comprehension of customer behavior in specific regions and countries. The report provides CAGR, revenue, production, consumption and other significant measurements and figures related to the global and regional markets. It shows how different type, application, and regional segments are advancing in the Animal Health Biotechnology market in terms of growth.

Some of the Key benefit in the report:Which are the five top players of the Animal Health Biotechnology market?How might the Animal Health Biotechnology showcase change in the following five years?Which item and application will take a largest part of the Animal Health Biotechnology showcase?What are the drivers and limitations of the Animal Health Biotechnology market?Which local market will show the most elevated development?What will be the CAGR and size of the Animal Health Biotechnology market all through the estimate period?

Enquire before purchasing this report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=115348

To know more about the Market Research Inc. Reports

Non-Bank Trade Finance Market https://www.digitaljournal.com/pr/non-bank-trade-finance-market-swot-analysis-business-growth-opportunities-by-top-companies-coface-trade-finance-global-clear-treasury-ccrmanager-bny-mellon

Finance Lease Market https://www.digitaljournal.com/pr/finance-lease-market-current-trends-future-aspect-analysis-2022-2030-hsbc-bank-sumitomo-mitsui-finance-and-leasing-bnp-paribas-leasing-solutions

Digital English Language Learning Market https://www.digitaljournal.com/pr/digital-english-language-learning-market-recent-trends-future-growth-high-demand-and-forecasts-2030-berlitz-languages-pearson-elt-sanako-corporation-ef-education-first-inlingua

Smart Waste Collection Market https://www.digitaljournal.com/pr/smart-waste-collection-market-analysis-share-size-recent-trends-and-demand-and-forecast-2030-bigbelly-inc-bin-e-covanta-holding-corporation-ecube-labs-co-ltd

Customization of this Report: This report can be customized as per your needs, Please contact our sales professional (sales@marketresearchinc.com), we will ensure you obtain the report which works for your needs

Contact UsMarket Research IncAuthor: KevinUS Address: 51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225-1818Write Us: sales@marketresearchinc.com

About UsMarket Research Inc. is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

This release was published on openPR.

Read more from the original source:
Animal Health Biotechnology Market Growth Prospects, Trends and Forecast up to 2030 - openPR

Granting legal rights and protections to non-human entities such as animals, trees and rivers is essential if countries are to tackle climate breakdown and biodiversity loss, experts have said.

The authors of a report titled Law in the Emerging Bio Age say legal frameworks have a key part to play in governing human interactions with the environment and biotechnology.

Ecuador and Bolivia have already enshrined rights for the natural world, while there is a campaign to make ecocide a prosecutable offence at the international criminal court. The report for the Law Society, the professional body for solicitors in England and Wales, explores how the relationship between humans and mother earth might be recalibrated in the future.

Dr Wendy Schultz, a futurist and report co-author, said: There is a growing understanding that something very different has to be done if our children are going to have a planet to live on that is in any way pleasant, much less survivable, so this is an expanding trend. Is it happening as fast as any of us would want? Possibly not, which is why its important to get the word out.

Her co-author, Dr Trish OFlynn, an interdisciplinary researcher who was previously the national lead for civil contingencies at the Local Government Association, said legal frameworks should be fit for a more than human future and developments such as genetic modification or engineering. This means covering everything from labradors to lab-grown brain tissue, rivers to robots.

We sometimes see ourselves as outside nature, that nature is something that we can manipulate, said OFlynn. But actually we are of nature, we are in nature, we are just another species. We happen to be at the top of the evolutionary tree in some ways, if you look at it in that linear kind of way, but actually the global ecosystem is much more powerful than we are. And I think thats beginning to come through in the way that we think about it.

An example of a right might be evolutionary development, where a species and individual is allowed to reach its full cognitive, emotional, social potential.

Such a right could apply to sows in intensive pig farming, calves taken away from their mothers and even pets, said OFlynn, adding: I say that as a dog lover. We do constrain their behaviour to suit us.

Developments in biotechnology also pose questions about the ethics of bringing back species from extinction or eradicating existing ones. Scientists are exploring reintroducing woolly mammoths and there has been discussion of wiping out mosquitoes, which carry malaria and other diseases.

The planet's most important stories. Get all the week's environment news - the good, the bad and the essential

We arent wise enough to manage all of these capabilities and to manage the ripple effects of decisions we make about our relationship with the living environment, said Schultz. Part of the issue is embedding some sort of framework for accountability and responsibility for the consequences of these things we do, and thats where law comes in.

The authors acknowledge potential resistance from very different traditions and beliefs in some western countries, compared with Ecuador and Bolivia, where rights to nature were granted under socialist governments and influenced by Indigenous beliefs (as was the 2019 ban on climbing Uluru in Australia).

Granting something that is culturally numinous rights just so you can preserve it gets us to a kind of valuation that, among other things, is a cultural shift away from the Judeo-Christian great chain of being dominion over nature, said Schultz. This is reconfiguring it to place us where we have always been and where we should be thinking of ourselves as belonging, as just a node in this greater web of life on the planet.

If that worldview can be enshrined in law, essentially granting personhood rights to the spirit of the river, the spirit of the trees or the spirit of the elephant, youre talking about enshrining a kind of neo-pantheism into 21st-century legal frameworks.

See more here:
Give legal rights to animals, trees and rivers, say experts - The Guardian

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The oligonucleotide synthesis market is expected to register a CAGR of 12.3% during the forecast period 2022-2027

The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

The usage of synthetic oligonucleotides has been increasing rapidly over the past decade, owing to several benefits offered by molecular diagnostics and growing clinical applications. The nucleic acid application techniques are the reference methods. They are very useful for carrying out molecular diagnosis in several diseases, like the detection of infectious diseases, such as hepatitis.

For instance, In January 2020, the Department of Biotechnology (DBT) initiated the "Genome India Project" (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.

In addition to this, in February 2021, the Centre for Process Innovation (CPI) launched a project in the Medicines Manufacturing Innovation Centre in the United Kingdom. This project aims to revolutionize the manufacturing of oligonucleotides through a collaboration with AstraZeneca, Exactmer, Novartis, and the United Kingdom Research & Innovation.

Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at a commercial scale as a result of this collaboration. Synthetic oligonucleotides also have significant clinical applications, primarily for the detection of autoimmune antibodies. There have been consistent developments in synthetic biology over the past few years, where synthetic oligonucleotides were used to develop assays for the detection of anti-double-stranded DNAs. Thus, all these factors are responsible for the growth of the oligonucleotide synthesis market.

However, there have been various instances in the past wherein, due to high complexities such as severe side effects, many drugs have been withdrawn or have failed in clinical trial phases. Such instances could become recurrent and may restrain market growth to a certain extent.

Key Market Trends

The Therapeutic Application Segment is Expected to Grow during the Forecast Period

Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. The increasing number of Food and Drug Administration-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs are factors expected to drive the growth of these therapeutics in the coming years.

The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological, infectious, and rare genetic disorders are expected to drive market growth.

Oligonucleotide therapeutics is an emerging drug modality, which consists of modified or unmodified short nucleic acid molecules, and includes antisense oligonucleotides (ASOs), small interfering RNA (siRNAs), microRNA (miRNAs), aptamers, and DNAzymes. For instance, as per the study published by the National Library of Medicine in March 2021, titled 'Recent Advances in Oligonucleotide Therapeutics in Oncology', currently, oligonucleotide therapeutics investigated in clinical trials include ASOs, siRNAs, miRNAs, aptamers, and DNAzymes. Their mechanisms of action differ, resulting in the correction of either abnormal expression or splicing patterns.

In addition to this, in March 2020, viltolarsen, developed by Japanese companies, was approved as a treatment for Duchenne muscular dystrophy. Moreover, in June 2022, GSK plc presented promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks' treatment in people with chronic hepatitis B (CHB). Such investigations are expected to boost the segment's growth in the years to come.

Nucleic acid-based therapeutics that regulate gene expression have been developed for clinical use at a steady pace for several decades, but in recent years the field has been accelerating and hence have, contributed to the segment's strong growth.

Market Dynamics

Market Drivers

Market Restraints

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

5 MARKET SEGMENTATION (Market Size by Value - USD million)

6 COMPETITIVE LANDSCAPE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/jzzw3u

The rest is here:
Oligonucleotide Synthesis Market Report 2022: Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies...